These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32407112)

  • 21. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
    Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
    Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
    Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
    J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of the toll-like receptor 8 gene in the Chinese raccoon dog (Nyctereutes procyonoides).
    Yang Y; Tong M; Yi L; Cheng Y; Zhang M; Cao Z; Wang J; Lin P; Cheng S
    Immunol Lett; 2016 Oct; 178():50-60. PubMed ID: 27481482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
    Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
    J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 - 2020.
    Kieffer ME; Patel AM; Hollingsworth SA; Seganish WM
    Expert Opin Ther Pat; 2020 Nov; 30(11):825-845. PubMed ID: 33052748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional polymorphisms of TLR8 are associated with hepatitis C virus infection.
    Wang CH; Eng HL; Lin KH; Liu HC; Chang CH; Lin TM
    Immunology; 2014 Apr; 141(4):540-8. PubMed ID: 24205871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of novel human Toll-like receptor 8 agonists.
    Kokatla HP; Sil D; Tanji H; Ohto U; Malladi SS; Fox LM; Shimizu T; David SA
    ChemMedChem; 2014 Apr; 9(4):719-23. PubMed ID: 24474703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
    Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
    Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Structural Analyses of Toll-like Receptor Sensing Single-stranded Nucleic Acids and Its Application].
    Shimizu T
    Yakugaku Zasshi; 2016; 136(2):173-8. PubMed ID: 26831789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation.
    Larangé A; Antonios D; Pallardy M; Kerdine-Römer S
    J Leukoc Biol; 2009 Apr; 85(4):673-83. PubMed ID: 19164127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
    Ren Q; Liu X; Yan G; Nie B; Zou Z; Li J; Chen Y; Wei Y; Huang J; Luo Z; Gu B; Goldmann S; Zhang J; Zhang Y
    J Med Chem; 2018 Feb; 61(3):1355-1374. PubMed ID: 29381358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
    Padilla-Salinas R; Anderson R; Sakaniwa K; Zhang S; Nordeen P; Lu C; Shimizu T; Yin H
    J Med Chem; 2019 Nov; 62(22):10221-10244. PubMed ID: 31687820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist.
    Herberhold S; Coch C; Zillinger T; Hommertgen B; Busch N; Schuberth C; Hartmann E; Wimmenauer V; Hagmann CA; Lüdenbach B; Schlee M; Bootz F; Hartmann G; Barchet W
    Antivir Ther; 2011; 16(5):751-8. PubMed ID: 21817197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses.
    Forsbach A; Nemorin JG; Montino C; Müller C; Samulowitz U; Vicari AP; Jurk M; Mutwiri GK; Krieg AM; Lipford GB; Vollmer J
    J Immunol; 2008 Mar; 180(6):3729-38. PubMed ID: 18322178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of a novel chemotype for human TLR8 inhibitors.
    Šribar D; Grabowski M; Murgueitio MS; Bermudez M; Weindl G; Wolber G
    Eur J Med Chem; 2019 Oct; 179():744-752. PubMed ID: 31284084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.
    Beesu M; Caruso G; Salyer AC; Khetani KK; Sil D; Weerasinghe M; Tanji H; Ohto U; Shimizu T; David SA
    J Med Chem; 2015 Oct; 58(19):7833-49. PubMed ID: 26351878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.